# Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer

> **NCT04033419** · PHASE2 · COMPLETED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 55 (actual)

## Conditions studied

- Cognitive Decline
- Chemo-brain

## Interventions

- **DRUG:** Memantine

## Key facts

- **NCT ID:** NCT04033419
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-25
- **Primary completion:** 2022-04-04
- **Final completion:** 2022-04-04
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2023-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04033419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04033419, "Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04033419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*